Strides Pharma Science Ltd. News, Corporate filings and Earnings/Conference Calls

Pharmaceuticals company Strides Pharma Science announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue at Rs 11,904 million, grew 17.0% YoY Gross margin at Rs 6,914 million, grew 18.1% YoY EBITDA grew 22.0% YoY to Rs 2,179 million with EBITDA margin at 18.3%, grew 75bps YoY US revenue at USD 77 million, grew 23.2% YoY Operational PAT at Rs 1,130 million, Grew 5x YoY Operational EPS at Rs 12.3, Grew 5x YoY FY25 Financial Highlights: Revenue at Rs 45,653 million, grew 17.2% YoY Gross margin at Rs 25,854 million, grew 20.5% YoY EBITDA grew 36.8% YoY to Rs 8,028 million with EBITDA margin at 17.6%, grew 252bps YoY US revenue at USD 291 million, grew 21.8% YoY Operational PAT at Rs 3,447 million, Grew 12x YoY Operational EPS at Rs 37.5, Grew 12x YoY Arun Kumar, Founder & Non-Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, "We are pleased to report a strong close to FY25, having successfully exceeded the outlook communicated across all key parameters. Our FY25 revenue grew by 17.2% YoY, outperforming our guidance of 12–15%, aided by strong US business performance. We also surpassed our EBITDA outlook, delivering Rs 8,028 million in FY25, reflecting enhanced operational efficiency and margin resilience post-demerger. We reduced Net debt by Rs 5,128 million, and our Net Debt-to-EBITDA ratio improved to 1.9x, well below the outlook given. The US business recorded USD 291 million in revenue, representing 21.8% YoY growth and exceeding the outlook. This was propelled by new product launches, steady base business, and a strong commercial execution framework. We also delivered an operating PAT of Rs 3,447 million for FY25, reflecting continued focus on profitability. The Board has recommended a dividend of Rs 4 per share for FY25, reflecting our strong. As we look ahead, we remain focused on the disciplined execution of our business strategies, underpinned by strong governance and a deep commitment to ESG — all aimed at delivering superior business outcomes and creating long-term value for all stakeholders." Result PDF

53.84% Fall from 52W High

High volume+gain today

Strides Pharma Science Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Strides Pharma Science Ltd. from all sources in a single place.